-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $34

Benzinga·04/01/2026 17:49:25
Listen to the news
Goldman Sachs analyst Corinne Johnson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $28 to $34.